The popularity of GLP-1 medications like semaglutide, commonly recognized as Ozempic and Wegovy, has significantly risen in recent years.Additionally, research has been expanding to explore potential additional benefits that these drugs may provide, beyond managing type 2 diabetes and promoting weight loss.New findings from a phase 3 clinical study suggest that semaglutide has the potential to alleviate knee osteoarthritis pain in individuals with obesity.The utilization of GLP-1 medications like Wegovy and Ozempic has significantly risen in recent years.Significantly boostedThese medications are primarily utilized for managing type 2 diabetes and facilitating weight loss; however, recent years have seen extensive research on the additional advantages offered by GLP-1 medications like semaglutide.Recent studies suggest that GLP-1 drugs could potentially provide neuroprotective advantages, reduce the risk of Alzheimer’s disease, and offer cardiovascular protection.Freshly released clinical trial results, featured in The New England Journal of Medicine, suggest that semaglutide could potentially alleviate knee osteoarthritis-related pain in individuals affected by obesity.Metalloproteases are enzymes that contain a metal ion as a cofactor to catalyze the hydrolysis of peptide bonds in proteins.
